This study addresses endosomal escape in oligonucleotide therapies and how engineered peptides can enhance intracellular drug delivery efficiency.

Epigenetic modifications such as DNA methylation play a key role in regulating gene expression. Emerging evidence suggests ...

The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be ...

Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Synthetic Oligonucleotides are set for rapid expansion in healthcare, food production, and data storage. The technology, vital in both existing and new markets, promises vast growth potential often ...

Epigenetic modifications such as DNA methylation play a key role in regulating gene expression. Emerging evidence suggests that intermediates ...

Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that ...

With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...

Epigenetic modifications such as DNA methylation play a key role in regulating gene expression. Emerging evidence suggests ...

ST Pharm has agreed a $56 million API supply deal with a US biotech for oligonucleotide therapeutics, boosting its order backlog and reflecting strong demand for advanced API manufacturing in global ...

ST Pharm has struck a deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for an upcoming oligonucleotide-based treatment.  | ST Pharm has struck a $56 ...

Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA ...